A new medicine against a certain form of ALS has now been approved by the EU Commission, reports P4 Göteborg.
The medicine tofersen, which is sold under the name Qalsody, can be used for treating patients with a rare, inherited form of ALS, which is estimated to be about two percent of all those affected by the disease.
There is a great need for new treatments and the medicine is seen by many as long-awaited, even if it concerns only a few patients.
Tofersen is a so-called gene therapy that works by reducing the disease-causing protein SOD-1. Studies suggest that it can slow down the progression of the disease.
